卡格利林提德通过大脑氨酸受体1和3降低体重
Alexandra Oliveira Carvas1, Andrea Leuthardt1, Patricia Kulka1
1Institute of Veterinary Physiology, University of Zurich, Switzerland.
EBioMedicine
|July 3, 2025
概括
卡格利林提德需要氨基林受体1和3 (AMY1R,AMY3R) 来产生减肥效应. 这项研究在RAMP1/3淘汰赛小鼠中研究了这些双氨酸-氨酸受体激活剂,揭示了特定的受体依赖性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肥胖问题研究研究
- 分子生物学分子生物学
背景情况:
- 氨酸 (AmyR) 和氨酸 (CTR) 受体协激剂正在研究用于治疗肥胖症.
- 氨基林通过涉及CTR和受体活性修饰蛋白 (RAMP1-3) 的异质二元受体复合体起作用.
研究的目的:
- 调查氨基林1和3 (AMY1R,AMY3R) 受体在调节卡格里林和鱼酸 (sCT) 作用中的作用.
- 评估RAMP1/3淘汰对这些双重激动剂的药理作用的影响.
主要方法:
- 使用RAMP1/3淘汰赛 (KO) 和野生类型 (WT) 老鼠食高脂肪饮食.
- 施用sCT或卡格里林提德皮下注射3周.
- 分析了体重,食物摄入量,神经元激活 (cFos) 和关键大脑区域的基因表达.
主要成果:
- 在WT小鼠中,卡格利林提德诱导了体重减轻,而sCT增加了体重减轻;RAMP1/3的缺失改变了这些效应.
- 这两种都减少了WT小鼠的食物摄入量.
- 神经元激活模式在WT和KO小鼠之间有所不同,在KO小鼠中,卡格利林提德对AP中的cFos信号的影响减少了. mRNA测序表明RAMP1/3参与突触功能和受体贩运.
结论:
- 卡格林丁的减肥效果取决于AMY1R和AMY3R.
- RAMP1和RAMP3在调解氨酸-氨酸受体激活剂的作用方面发挥着不同的作用.
相关概念视频
Regulation of Food Intake
500
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
500
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Antidepressant Drugs: MAOIs and Other Agents
373
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
373
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
412
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
412


